Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling for Eating Disorders in Type 1 Diabetes
This study is testing two different approaches to help people with Type 1 Diabetes and eating disorders: Acceptance and Commitment Therapy (ACT) and Supportive Diabetes Counseling. You might also be placed in a waitlist group. The goal is to see if these treatments can improve blood sugar control (glycemic control), reduce eating disorder symptoms, and help with managing diabetes. To join, you need to be between 16 and 50 years old, have Type 1 Diabetes, and experience binge eating or problematic weight control behaviors, including withholding insulin. The study is currently unclear on its recruitment status, but plans to enroll 235 people.
- Study design
- This is a randomized controlled trial comparing two active treatments (ACT and Supportive Diabetes Counseling) to a waitlist control group, involving 235 participants.
- What's involved
- If you are in an active treatment group, you will have 12 therapy sessions over 12-16 weeks and use a mobile phone for support between sessions. You will also have assessments at several points over 36 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 6 months after treatment, with assessments at 1 month, 3 months, and 6 months post-treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Rhonda Merwin, PhD · PRINCIPAL_INVESTIGATOR · Duke University faculty
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in glycemic control as indexed by continuous glucose monitoring (CGM)baseline, 6 weeks, 12 weeks, 36 weeks
CGM indices of time in target glycemic range, mean blood sugar, frequency of Level 1 and 2 hyperglycemia and blood glucose variability
- Change in eating disorder symptoms as indexed by the Diabetes Eating Problems Survey-Revised (DEPS-R)baseline, 12 weeks, 16 weeks, 24 weeks, 36 weeks
Severity of eating and body image concerns, frequency of engagement in maladaptive eating and weight control behaviors, specifically in the context of diabetes. Scores range from 0-80, with higher scores indicating greater symptom severity (worse outcome).
- Change in diabetes self-management as indexed by the Diabetes Self-Management Questionnairebaseline, 12 weeks, 16 weeks, 24 weeks, 36 weeks
Engagement in activities necessary to manage diabetes, including checking blood sugar and administering insulin. Scores range from 0-10 with higher scores indicating better self-management.
- Change in glycemic control as indexed by hemoglobin A1c (HbA1c)baseline, 24 weeks, 36 weeks
Glycated hemoglobin (percentage of red blood cells that are glycated providing an estimate of average blood glucose over 3 months)